🔎 Trials Near Me

Beranda › Obesitas › Idaho

Uji klinis Obesitas di Idaho

21 studi untuk Obesitas mencari peserta di lokasi di Idaho.

Kota di Idaho

Teks studi resmi (Bahasa Inggris)

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

  • Elite Clinical Trials - Blackfoot /ID# 282042, Blackfoot
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07752979

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

  • Solaris Clinical Research, Meridian
Menerima pesertaFase 3
Usia 8 hingga 18 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07253285

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Grand Teton Research Group, Idaho Falls
Menerima pesertaFase 3
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06937099

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  • Grand Teton Research Group, Idaho Falls
Menerima pesertaFase 3
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06937086

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  • Family First Medical Center, Idaho Falls
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07392190

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  • Velocity Clinical Research - Boise, Meridian
Menerima pesertaFase 3
Usia 45 hingga 99 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07037433

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

  • Medical Research Partners, Ammon
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07353931

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  • Medical Research Partners, Ammon
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07589608

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  • AURORA-1 Clinical Site, Boise
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  • AURORA-2 Clinical Site, Boise
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07743450

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  • High Desert Heart and Vascular, Meridian
Menerima pesertaFase 3
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07037459

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  • Elite Clinical Trials, Blackfoot
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT07351058

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

  • Elite Clinical Trials, Rexburg
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06897475

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

  • ACCOMPLISH-2 Research Site, Meridian
Menerima pesertaFase 3Sukarelawan sehat diterima
Usia 18 hingga 79 · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT07654374

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  • Medical Research Partners, Ammon
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06143956

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  • Solaris Clinical Research, Meridian
Menerima pesertaFase 3
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07684235

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  • Solaris Clinical Research, Meridian
Menerima pesertaFase 3
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 27 Agu 2026 · NCT07575399

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  • High Desert Heart and Vascular PLLC, Meridian
  • St. Luke's Idaho Cardiology Associates, Meridian
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT07567001

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

  • ACCOMPLISH-1 Research Site, Meridian
  • ACCOMPLISH-1 Research Site, Rexburg
Menerima pesertaFase 3
Usia 18 hingga 79 · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT07654361

Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention

  • Boise VA Medical Center, Boise
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT06390345

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

  • Elite Clinical Trials, Blackfoot
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jul 2026 · NCT07481630

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.